Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Hope Heller, Stefan Bohlen et al.|The Lancet Neurology|2018Cited by 108
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension StudySamuel Frank, Brad A. Racette, Stephanie Leyva et al.|CNS Drugs|2022Cited by 31
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington DiseaseAndrew McGarry, Michael R. Hayden, Juha‐Matti Savola et al.|Journal of Huntington s Disease|2020Cited by 22